Search research articles
Contact Us
Filters
Showing results (71-80 of 159) with videos related to
Page
of 16
Sort By:
European Journal of Preventive Cardiology
|
June 24, 2026
Regional fat distribution as a determinant of mortality in populations with left ventricular systolic dysfunction: challenging the obesity paradox
Shaun Khanna, William Ho, Fumihiko Takeuchi, et al.
BMJ Open
|
December 12, 2025
DIVINE-pilot trial: a phase 2 multicentre, randomised pilot trial of pharmacotherapy and physical activity monitoring conducted in women with recent gestational diabetes and increased risk of type 2 diabetes recruited from tertiary referral hospitals in Australia
Angela Xun-Nan Chen, Vivian Y Lee, Katherine Donges, et al.
Kidney International
|
May 30, 2020
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
JingWei Li, Bruce Neal, Vlado Perkovic, et al.
JACC. Advances
|
May 21, 2026
Associations of Central Adiposity With Subclinical Coronary Calcification and Disease Progression: Meta-Analysis of 68,629 Participants
Shaun Khanna, Gurkeerat Mann, Sohaib Virk, et al.
Cardiovascular Diabetology
|
September 23, 2022
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
Sok Cin Tye, Niels Jongs, Steven G Coca, et al.
Open Heart
|
September 5, 2015
Subtle increases in heart size persist into adulthood in growth restricted babies: the Cardiovascular Risk in Young Finns Study
Clare Arnott, Michael R Skilton, Saku Ruohonen, et al.
JACC. Cardiovascular Imaging
|
July 8, 2026
Serial Changes in Epicardial Adipose Tissue Attenuation Identify Residual Atherosclerotic Risk Independent of LDL Lowering: A Post Hoc Analysis of the CAUGHT-CAD Trial
Shaun Khanna, Edwin Xu, Cheng Hwee Soh, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)
|
July 26, 2020
Rationale, design, and baseline characteristics of the Salt Substitute in India Study (SSiIS): The protocol for a double-blinded, randomized-controlled trial
Sudhir Raj Thout, Jie Yu, Maoyi Tian, et al.
Journal of the American Heart Association
|
December 2, 2021
Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
Taha Sen, Jingwei Li, Brendon L Neuen, et al.
Nature Reviews. Cardiology
|
June 16, 2026
Role of systemic and epicardial adipose tissue in cardiometabolic disease
Shaun Khanna, Gurkeerat Mann, Aditya Bhat, et al.
Page
of 16
Search research articles
Search
Showing results (71-80 of 159) with videos related to
Sort By:
Page
of 16
European Journal of Preventive Cardiology
|
June 24, 2026
Regional fat distribution as a determinant of mortality in populations with left ventricular systolic dysfunction: challenging the obesity paradox
Shaun Khanna, William Ho, Fumihiko Takeuchi, et al.
BMJ Open
|
December 12, 2025
DIVINE-pilot trial: a phase 2 multicentre, randomised pilot trial of pharmacotherapy and physical activity monitoring conducted in women with recent gestational diabetes and increased risk of type 2 diabetes recruited from tertiary referral hospitals in Australia
Angela Xun-Nan Chen, Vivian Y Lee, Katherine Donges, et al.
Kidney International
|
May 30, 2020
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
JingWei Li, Bruce Neal, Vlado Perkovic, et al.
JACC. Advances
|
May 21, 2026
Associations of Central Adiposity With Subclinical Coronary Calcification and Disease Progression: Meta-Analysis of 68,629 Participants
Shaun Khanna, Gurkeerat Mann, Sohaib Virk, et al.
Cardiovascular Diabetology
|
September 23, 2022
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
Sok Cin Tye, Niels Jongs, Steven G Coca, et al.
Open Heart
|
September 5, 2015
Subtle increases in heart size persist into adulthood in growth restricted babies: the Cardiovascular Risk in Young Finns Study
Clare Arnott, Michael R Skilton, Saku Ruohonen, et al.
JACC. Cardiovascular Imaging
|
July 8, 2026
Serial Changes in Epicardial Adipose Tissue Attenuation Identify Residual Atherosclerotic Risk Independent of LDL Lowering: A Post Hoc Analysis of the CAUGHT-CAD Trial
Shaun Khanna, Edwin Xu, Cheng Hwee Soh, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)
|
July 26, 2020
Rationale, design, and baseline characteristics of the Salt Substitute in India Study (SSiIS): The protocol for a double-blinded, randomized-controlled trial
Sudhir Raj Thout, Jie Yu, Maoyi Tian, et al.
Journal of the American Heart Association
|
December 2, 2021
Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
Taha Sen, Jingwei Li, Brendon L Neuen, et al.
Nature Reviews. Cardiology
|
June 16, 2026
Role of systemic and epicardial adipose tissue in cardiometabolic disease
Shaun Khanna, Gurkeerat Mann, Aditya Bhat, et al.
Page
of 16